Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Consensus Price Target of $10.00 According to Brokerages

Shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several equities analysts have weighed in on ATHE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Friday, July 17th. LADENBURG THALM/SH SH initiated coverage on shares of Alterity Therapeutics in a research report on Tuesday, June 16th. They set a “buy” rating and a $10.00 target price for the company. UBS Group set a $12.00 target price on shares of Alterity Therapeutics in a research note on Tuesday, August 11th. Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a report on Wednesday, June 17th. Finally, Lake Street Capital began coverage on shares of Alterity Therapeutics in a report on Tuesday, September 15th. They issued a “buy” rating and a $10.00 price target on the stock.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its position in Alterity Therapeutics stock. Greenleaf Trust lifted its stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) by 93.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 62,000 shares of the company’s stock after acquiring an additional 30,000 shares during the period. Greenleaf Trust owned approximately 0.70% of Alterity Therapeutics worth $333,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Price Performance

Shares of NASDAQ:ATHE opened at $3.45 on Wednesday. The business’s 50 day moving average is $4.28 and its 200 day moving average is $4.35. Alterity Therapeutics has a 12-month low of $2.66 and a 12-month high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE) last announced its earnings results on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. Analysts forecast that Alterity Therapeutics will post -0.12 EPS for the current fiscal year.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited (NASDAQ: ATHE) is an Australia-based clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on abnormal protein misfolding and aggregation, biological processes associated with disorders such as multiple system atrophy and Parkinson’s disease.

The company’s lead drug candidate, ATH-434, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative conditions.